Also, a humanized monoclonal antibody (FG-3019) directed at CCN2 has undergone safety trials in patients with diabetes mellitus and microalbuminuria [50], and is currently being tested in patients with idiopathic pulmonary fibrosis and liver fibrosis. Here, CCN2 is linked to idiopathic pulmonary fibrosis.